ERSP process
This article was originally published in The Tan Sheet
Executive Summary
Parties involved in ERSP cases have the opportunity to participate in the review process under specific circumstances, counter to comments included in an article in the Oct. 16 issue of "The Tan Sheet" (1"The Tan Sheet" Oct. 16, 2006, p. 13). "Under ERSP's policies and procedures, the person or legal entity that initiates the inquiry has the option of actively participating in the review process, but is not required to do so," ERSP Director Peter Marinello tells "The Tan Sheet." When parties involved in cases choose to participate, they have access to all non-confidential submissions and can contribute comments to the record, Marinello says. However, "parties that elect to remain anonymous may not review the submissions or contribute to the case record," he adds...
You may also be interested in...
Demand Letters, NAD Review Can Check Firms’ Claims Without Court – Lawyer
Dietary supplement and nutritional product firms challenging competitors' claims have several options more cost-effective than litigation, advises Ivan Wasserman, a partner at Kelly Drye Collier Shannon (Washington, D.C.)
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.